Health Care and Life Sciences Companies Should Take More FCA Cases to Trial

September.19.2022

In this Law360 article, partner Franklin Monsour Jr. outlines the reasons health care and life sciences companies may want to contest increasingly common False Claims Act cases at trial.

Franklin notes that there may be particular incentive to fight whistleblower cases at trial when they involve claims under the Anti-Kickback Statute. “More defendants should fight these cases at trial,” Franklin writes.